EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Entrada Therapeutics's Enterprise Value is $148.4 Mil.
Entrada Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $134.2 Mil. Therefore, Entrada Therapeutics's EV-to-FCF for today is 1.11.
The historical rank and industry rank for Entrada Therapeutics's EV-to-FCF or its related term are showing as below:
TRDA'
s EV-to-FCF Range Over the Past 10 Years
Min: -0.13 Med: 1.55 Max: 2.65
Current: 1.11
During the past 5 years, the highest EV-to-FCF of Entrada Therapeutics was 2.65. The lowest was -0.13. And the median was 1.55.
TRDA's EV-to-FCF is ranked better than 61.22% of 392
companies
in the Biotechnology industry
Industry Median: 4.22
vs TRDA: 1.11
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-24), Entrada Therapeutics's stock price is $12.43.
Entrada Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.260. Therefore, Entrada Therapeutics's PE Ratio for today is At Loss.
Entrada Therapeutics EV-to-FCF Historical Data
The historical data trend for Entrada Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Entrada Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Entrada Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entrada Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entrada Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Entrada Therapeutics's EV-to-FCF falls into.
Entrada Therapeutics EV-to-FCF Calculation
Entrada Therapeutics's EV-to-FCF for today is calculated as:
Entrada Therapeutics's current Enterprise Value is $148.4 Mil.
Entrada Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $134.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Entrada Therapeutics's PE Ratio for today is calculated as:
Entrada Therapeutics's share price for today is $12.43.
Entrada Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.260.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Entrada Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Entrada Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Entrada Therapeutics (Entrada Therapeutics) Business Description
Entrada Therapeutics Inc mission is to transform the treatment of devastating diseases and improve patients quality of life by developing intracellular biologics. Leveraging its proprietary Endosomal Escape Vehicle platform, Entrada is creating a diverse and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to efficiently target and engage underlying drivers of diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TRDA has been successfully added to your 